Clinical Trials and Observational Studies
Active Enrollment
The Effect of KNO3 Compared to KCl on Oxygen Uptake in Heart Failure with Preserved Ejection Fraction
This study will test whether a drug called mavacamten can lower blood levels of cardiac troponin (a marker of heart muscle injury) and/or NT-proBNP (a marker of heart wall stress).
The BASIC Study: Blood And Sweat chemistry In Cardiology
Prospective evaluation and validation of an applied ATTR-CM Machine Learning model to a health system electronic health record (EHR)
Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), which is a disease caused by change in a protein called transthyretin (TTR).
History of heart failure with preserved ejection fraction and diabetes mellitus
Proteomics of Baroreceptor Reflex Dysfunction
HAPI-HF Study: pHysiological signals, Activity and Posture for surface mounted Insertable Cardiac Monitor in Heart Failure
Enrollment Complete
Prevalence Of Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy
Effects of dapagliflozin on biomarkers, symptoms and functional status in patients with type 2 diabetes or pre-diabetes, and preserved ejection fraction heart failure (PRESERVED-HF Trial)
Visceral Congestion in Heart Failure Study
Real Life Multimarker Monitoring in Patients with Heart Failure
American Heart Association Go Red For Women
The Multi-Ethnic Study of Atherosclerosis
A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure
A randomized, blinded, placebo-controlled, parallel group, multicentre study to assess safety and tolerability of AZD4831 in patiens with Heart Failure with preserved Ejection Fraction, HFpEF
A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetics and pharmacodynamic effects of the oral partial adenosine A1 receptor agonist neladenoson bialanate
A Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy, Safety, and Tolerability of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Comparison to Placebo in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)
A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction
A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure
Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 over 12 Weeks in Patients with Heart Failure with Preserved Ejection Fraction
A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy
A Global, Multi-Center, Longitudinal, Observational Survey of Patients with Documented Transthyretin (TTR) Mutations or Wild-Type TTR Amyloidosis
Characterizing HIV-related Diastolic Dysfunction
A randomized, subject and investigator-blind, placebo-controlled study of CLR325 in chronic stable heart failure patients
A Longitudinal Evaluation of Disease & Fibrosis Biomarkers in Different Groups of Heart Failure Patients to Enhance the Early Clinical Development of Compounds with Anti-fibrotic Activity in the Heart
A Phase 3 Multicenter, Randomized, Double-Blind, Extension Study to Evaluate the Safety of Daily Oral Dosing of Tafamidis Meglumine (PF-06291826) 20 mg or 80 mg in Subjects Diagnosed With Transthyretin Cardiomyopathy (TTR-CM)
OMICS of Cardiac Structure and Function
A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascular disease
REVAMP Clinical Study (Remodeling the Left Ventricle with Atrial Modulated Pacing)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopa